APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

VEGFR-2 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global VEGFR-2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025187 pages

Choose your research edition.

Industry ResearchVEGFR-2 Inhibitor Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGFR-2 Inhibitor Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal VEGFR-2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGFR-2 Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGFR-2 Inhibitor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global VEGFR-2 Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for VEGFR-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VEGFR-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VEGFR-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for VEGFR-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of VEGFR-2 Inhibitor include AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Exelixis, Novartis, Pfizer, Jiangsu Hengrui Pharmaceuticals and Chia Tai Tianqing, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global VEGFR-2 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VEGFR-2 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VEGFR-2 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the VEGFR-2 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

VEGFR-2 Inhibitor Segment by Company

AstraZeneca

Bayer

Boehringer Ingelheim

Eisai

Exelixis

Novartis

Pfizer

Jiangsu Hengrui Pharmaceuticals

Chia Tai Tianqing

VEGFR-2 Inhibitor Segment by Type

Sorafenib

Sunitinib

Nintedanib

Lenvatinib

Cabozantinib

Vandetanib

Apatinib

Other

VEGFR-2 Inhibitor Segment by Application

Ophthalmic Diseases

Cancer Therapy

Other

VEGFR-2 Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGFR-2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGFR-2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGFR-2 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the VEGFR-2 Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of VEGFR-2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of VEGFR-2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of VEGFR-2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. VEGFR-2 Inhibitor Industry Trends Table 2. VEGFR-2 Inhibitor Industry Drivers Table 3. VEGFR-2 Inhibitor Industry Opportunities and Challenges Table 4. VEGFR-2 Inhibitor Industry Restraints Table 5. Global VEGFR-2 Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global VEGFR-2 Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global VEGFR-2 Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global VEGFR-2 Inhibitor Sales Market Share by Manufacturers Table 9. Global VEGFR-2 Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global VEGFR-2 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global VEGFR-2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global VEGFR-2 Inhibitor Manufacturers, Product Type & Application Table 13. Global VEGFR-2 Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global VEGFR-2 Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Sorafenib Table 17. Major Manufacturers of Sunitinib Table 18. Major Manufacturers of Nintedanib Table 19. Major Manufacturers of Lenvatinib Table 20. Major Manufacturers of Cabozantinib Table 21. Major Manufacturers of Vandetanib Table 22. Major Manufacturers of Apatinib Table 23. Major Manufacturers of Other Table 24. Global VEGFR-2 Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global VEGFR-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 26. Global VEGFR-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 27. Global VEGFR-2 Inhibitor Sales Market Share by Type (2021-2026) Table 28. Global VEGFR-2 Inhibitor Sales Market Share by Type (2027-2032) Table 29. Global VEGFR-2 Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 30. Global VEGFR-2 Inhibitor Revenue by Type (2021-2026) & (K Units) Table 31. Global VEGFR-2 Inhibitor Revenue by Type (2027-2032) & (K Units) Table 32. Global VEGFR-2 Inhibitor Revenue Market Share by Type (2021-2026) Table 33. Global VEGFR-2 Inhibitor Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Ophthalmic Diseases Table 35. Major Manufacturers of Cancer Therapy Table 36. Major Manufacturers of Other Table 37. Global VEGFR-2 Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global VEGFR-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 39. Global VEGFR-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 40. Global VEGFR-2 Inhibitor Sales Market Share by Application (2021-2026) Table 41. Global VEGFR-2 Inhibitor Sales Market Share by Application (2027-2032) Table 42. Global VEGFR-2 Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 43. Global VEGFR-2 Inhibitor Revenue by Application (2021-2026) & (K Units) Table 44. Global VEGFR-2 Inhibitor Revenue by Application (2027-2032) & (K Units) Table 45. Global VEGFR-2 Inhibitor Revenue Market Share by Application (2021-2026) Table 46. Global VEGFR-2 Inhibitor Revenue Market Share by Application (2027-2032) Table 47. Global VEGFR-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global VEGFR-2 Inhibitor Sales by Region (2021-2026) & (K Units) Table 49. Global VEGFR-2 Inhibitor Sales Market Share by Region (2021-2026) Table 50. Global VEGFR-2 Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 51. Global VEGFR-2 Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 52. North America VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. North America VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 54. North America VEGFR-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 55. Europe VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Europe VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 57. Europe VEGFR-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 58. Asia Pacific VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Asia Pacific VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 60. Asia Pacific VEGFR-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 61. South America, Middle East and Africa VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. South America, Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 63. South America, Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 64. Global VEGFR-2 Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global VEGFR-2 Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 66. Global VEGFR-2 Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 67. Global VEGFR-2 Inhibitor Revenue Market Share by Region (2021-2026) Table 68. Global VEGFR-2 Inhibitor Revenue Market Share by Region (2027-2032) Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AstraZeneca VEGFR-2 Inhibitor Product Portfolio Table 73. AstraZeneca Recent Development Table 74. Bayer Company Information Table 75. Bayer Business Overview Table 76. Bayer VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer VEGFR-2 Inhibitor Product Portfolio Table 78. Bayer Recent Development Table 79. Boehringer Ingelheim Company Information Table 80. Boehringer Ingelheim Business Overview Table 81. Boehringer Ingelheim VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Boehringer Ingelheim VEGFR-2 Inhibitor Product Portfolio Table 83. Boehringer Ingelheim Recent Development Table 84. Eisai Company Information Table 85. Eisai Business Overview Table 86. Eisai VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Eisai VEGFR-2 Inhibitor Product Portfolio Table 88. Eisai Recent Development Table 89. Exelixis Company Information Table 90. Exelixis Business Overview Table 91. Exelixis VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Exelixis VEGFR-2 Inhibitor Product Portfolio Table 93. Exelixis Recent Development Table 94. Novartis Company Information Table 95. Novartis Business Overview Table 96. Novartis VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Novartis VEGFR-2 Inhibitor Product Portfolio Table 98. Novartis Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Pfizer VEGFR-2 Inhibitor Product Portfolio Table 103. Pfizer Recent Development Table 104. Jiangsu Hengrui Pharmaceuticals Company Information Table 105. Jiangsu Hengrui Pharmaceuticals Business Overview Table 106. Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Product Portfolio Table 108. Jiangsu Hengrui Pharmaceuticals Recent Development Table 109. Chia Tai Tianqing Company Information Table 110. Chia Tai Tianqing Business Overview Table 111. Chia Tai Tianqing VEGFR-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Chia Tai Tianqing VEGFR-2 Inhibitor Product Portfolio Table 113. Chia Tai Tianqing Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. VEGFR-2 Inhibitor Distributors List Table 117. VEGFR-2 Inhibitor Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. VEGFR-2 Inhibitor Product Image Figure 2. Global VEGFR-2 Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGFR-2 Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global VEGFR-2 Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global VEGFR-2 Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 VEGFR-2 Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Sorafenib Image Figure 9. Sunitinib Image Figure 10. Nintedanib Image Figure 11. Lenvatinib Image Figure 12. Cabozantinib Image Figure 13. Vandetanib Image Figure 14. Apatinib Image Figure 15. Other Image Figure 16. Global VEGFR-2 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global VEGFR-2 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global VEGFR-2 Inhibitor Sales Market Share by Type (2021-2032) Figure 19. Global VEGFR-2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global VEGFR-2 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global VEGFR-2 Inhibitor Revenue Market Share by Type (2021-2032) Figure 22. Ophthalmic Diseases Image Figure 23. Cancer Therapy Image Figure 24. Other Image Figure 25. Global VEGFR-2 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global VEGFR-2 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global VEGFR-2 Inhibitor Sales Market Share by Application (2021-2032) Figure 28. Global VEGFR-2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 29. Global VEGFR-2 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global VEGFR-2 Inhibitor Revenue Market Share by Application (2021-2032) Figure 31. North America VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. North America VEGFR-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 33. U.S. VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Canada VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Mexico VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe VEGFR-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 38. Germany VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. France VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. U.K. VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Italy VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Netherlands VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific VEGFR-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 45. China VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Japan VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Korea VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Southeast Asia VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. India VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Australia VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa VEGFR-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 53. Brazil VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. South Africa VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Saudi Arabia VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Turkey VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Argentina VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 58. UAE VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Egypt VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Chile VEGFR-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Global VEGFR-2 Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global VEGFR-2 Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America VEGFR-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 64. North America VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe VEGFR-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 66. Europe VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific VEGFR-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa VEGFR-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. VEGFR-2 Inhibitor Value Chain Figure 72. Manufacturing Cost Structure Figure 73. VEGFR-2 Inhibitor Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Sorafenib
  • Sunitinib
  • Nintedanib
  • Lenvatinib
  • Cabozantinib
  • Vandetanib
  • Apatinib
  • Other
Applications
  • Ophthalmic Diseases
  • Cancer Therapy
  • Other
Companies covered
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Eisai
  • Exelixis
  • Novartis
  • Pfizer
  • Jiangsu Hengrui Pharmaceuticals
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global VEGFR-2 Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global VEGFR-2 Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global VEGFR-2 Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global VEGFR-2 Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global VEGFR-2 Inhibitor Market Dynamics
  1. 2.1 VEGFR-2 Inhibitor Industry Trends
  2. 2.2 VEGFR-2 Inhibitor Industry Drivers
  3. 2.3 VEGFR-2 Inhibitor Industry Opportunities and Challenges
  4. 2.4 VEGFR-2 Inhibitor Industry Restraints
3 VEGFR-2 Inhibitor Market by Manufacturers
  1. 3.1 Global VEGFR-2 Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global VEGFR-2 Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global VEGFR-2 Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global VEGFR-2 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global VEGFR-2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global VEGFR-2 Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global VEGFR-2 Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global VEGFR-2 Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 VEGFR-2 Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 VEGFR-2 Inhibitor Tier 1, Tier 2, and Tier 3
4 VEGFR-2 Inhibitor Market by Type
  1. 4.1 VEGFR-2 Inhibitor Type Introduction
  2. 4.1.1 Sorafenib
  3. 4.1.2 Sunitinib
  4. 4.1.3 Nintedanib
  5. 4.1.4 Lenvatinib
  6. 4.1.5 Cabozantinib
  7. 4.1.6 Vandetanib
  8. 4.1.7 Apatinib
  9. 4.1.8 Other
  10. 4.2 Global VEGFR-2 Inhibitor Sales by Type
  11. 4.2.1 Global VEGFR-2 Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global VEGFR-2 Inhibitor Sales by Type (2021-2032)
  13. 4.2.3 Global VEGFR-2 Inhibitor Sales Market Share by Type (2021-2032)
  14. 4.3 Global VEGFR-2 Inhibitor Revenue by Type
  15. 4.3.1 Global VEGFR-2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global VEGFR-2 Inhibitor Revenue by Type (2021-2032)
  17. 4.3.3 Global VEGFR-2 Inhibitor Revenue Market Share by Type (2021-2032)
5 VEGFR-2 Inhibitor Market by Application
  1. 5.1 VEGFR-2 Inhibitor Application Introduction
  2. 5.1.1 Ophthalmic Diseases
  3. 5.1.2 Cancer Therapy
  4. 5.1.3 Other
  5. 5.2 Global VEGFR-2 Inhibitor Sales by Application
  6. 5.2.1 Global VEGFR-2 Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VEGFR-2 Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global VEGFR-2 Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global VEGFR-2 Inhibitor Revenue by Application
  10. 5.3.1 Global VEGFR-2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global VEGFR-2 Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global VEGFR-2 Inhibitor Revenue Market Share by Application (2021-2032)
6 Global VEGFR-2 Inhibitor Sales by Region
  1. 6.1 Global VEGFR-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VEGFR-2 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global VEGFR-2 Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global VEGFR-2 Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America VEGFR-2 Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe VEGFR-2 Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific VEGFR-2 Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa VEGFR-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global VEGFR-2 Inhibitor Revenue by Region
  1. 7.1 Global VEGFR-2 Inhibitor Revenue by Region
  2. 7.1.1 Global VEGFR-2 Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global VEGFR-2 Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global VEGFR-2 Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global VEGFR-2 Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America VEGFR-2 Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe VEGFR-2 Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific VEGFR-2 Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa VEGFR-2 Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa VEGFR-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca VEGFR-2 Inhibitor Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer VEGFR-2 Inhibitor Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim VEGFR-2 Inhibitor Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Eisai
  20. 8.4.1 Eisai Company Information
  21. 8.4.2 Eisai Business Overview
  22. 8.4.3 Eisai VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eisai VEGFR-2 Inhibitor Product Portfolio
  24. 8.4.5 Eisai Recent Developments
  25. 8.5 Exelixis
  26. 8.5.1 Exelixis Company Information
  27. 8.5.2 Exelixis Business Overview
  28. 8.5.3 Exelixis VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Exelixis VEGFR-2 Inhibitor Product Portfolio
  30. 8.5.5 Exelixis Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis VEGFR-2 Inhibitor Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer VEGFR-2 Inhibitor Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Jiangsu Hengrui Pharmaceuticals
  44. 8.8.1 Jiangsu Hengrui Pharmaceuticals Company Information
  45. 8.8.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  46. 8.8.3 Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Product Portfolio
  48. 8.8.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  49. 8.9 Chia Tai Tianqing
  50. 8.9.1 Chia Tai Tianqing Company Information
  51. 8.9.2 Chia Tai Tianqing Business Overview
  52. 8.9.3 Chia Tai Tianqing VEGFR-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Chia Tai Tianqing VEGFR-2 Inhibitor Product Portfolio
  54. 8.9.5 Chia Tai Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 VEGFR-2 Inhibitor Value Chain Analysis
  2. 9.1.1 VEGFR-2 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 VEGFR-2 Inhibitor Production Mode & Process
  6. 9.2 VEGFR-2 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 VEGFR-2 Inhibitor Distributors
  9. 9.2.3 VEGFR-2 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst